Scroll back to top

Fecal occult blood testing

Close

Fecal occult blood testing

Annual screening with iFOBT has been shown in peer-reviewed literature to detect a majority of prevalent colorectal cancer (CRC) in an asymptomatic population at the time of testing, and is an acceptable option for CRC screening in average-risk adults who are 45 years and older.

  • No dietary or medicinal restrictions1
  • Lower GI specific2
  • Easy-to-use
  • Greater sensitivity and specificity than GT2
  • LabCorp iFOBT:
    • Sensitivity: 98.8% / Specificity 99.6%3
    • Improves patient participation in screening2
    • Specific to human globin2
    • Annual screening test4
    • DRE sample indication1

LabCorp offers the Fecal Occult Blood Immunoassay.

For more information, please download the following brochure:

Reference

  1. Polymedco. FOBT-CHEK OC. February 2008. PN 51396-03.
  2. Allison JE. The role of fecal occult blood testing in screening for colorectal cancer. Practical Gastroenterol. 2007 Jun; 31(6):20-32
  3. Daily JM, Bay CP, Levy BT. Evaluation of fecal immunochemical tests for CRC screening. J Prim Care Community Health. 2013;4(4):245-250.
  4. American Cancer Society. American Cancer Society Guideline for Colorectal Cancer Screening. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-st.... Accessed June 5, 2018